Literature DB >> 11389087

Extensive somatic microsatellite mutations in normal human tissue.

S Vilkki1, J L Tsao, A Loukola, M Pöyhönen, O Vierimaa, R Herva, L A Aaltonen, D Shibata.   

Abstract

Microsatellite (MS) instability occurs in tumors with DNA mismatch repair (MMR) deficiencies but is typically absent in adjacent normal tissue. However, MS mutations have been observed in normal tissues from rare individuals with congenital MMR deficiencies. Autopsy tissues from a 4-year-old with congenital MMR deficiency (MLH1-/-) were examined for MS mutations. Insertions and deletions were observed in CA-repeat MS loci. Approximately 0.26 to 1.4 mutations per MS locus per cell were estimated to be present in normal heart, lymph node, kidney, and bladder epithelium. These findings illustrate that phenotypically normal MMR-deficient cells commonly accumulate MS mutations. Loss of MMR and the accumulation of some MS mutations may occur early in MMR-deficient tumor progression, even before a gatekeeper mutation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11389087

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

1.  Hypermutability at a poly(A/T) tract in the human germline.

Authors:  A L Bacon; M G Dunlop; S M Farrington
Journal:  Nucleic Acids Res       Date:  2001-11-01       Impact factor: 16.971

2.  Early onset brain tumor and lymphoma in MSH2-deficient children.

Authors:  Gaëlle Bougeard; Françoise Charbonnier; Alexandre Moerman; Cosette Martin; Marie M Ruchoux; Nathalie Drouot; Thierry Frébourg
Journal:  Am J Hum Genet       Date:  2003-01       Impact factor: 11.025

3.  In vivo somatic microsatellite mutations identified in non-malignant human tissue.

Authors:  Kathy Mann; Celia Donaghue; Caroline Mackie Ogilvie
Journal:  Hum Genet       Date:  2003-09-18       Impact factor: 4.132

Review 4.  Single-cell sequencing-based technologies will revolutionize whole-organism science.

Authors:  Ehud Shapiro; Tamir Biezuner; Sten Linnarsson
Journal:  Nat Rev Genet       Date:  2013-07-30       Impact factor: 53.242

5.  MLH1 and MSH2 mutations in Colombian families with hereditary nonpolyposis colorectal cancer (Lynch syndrome)--description of four novel mutations.

Authors:  Alejandro Giraldo; Andrea Gómez; Gustavo Salguero; Herbert García; Fabio Aristizábal; Oscar Gutiérrez; Luis Alberto Angel; Jorge Padrón; Carlos Martínez; Humberto Martínez; Omar Malaver; Luis Flórez; Rosa Barvo
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

Review 6.  Syndrome of early onset colon cancers, hematologic malignancies & features of neurofibromatosis in HNPCC families with homozygous mismatch repair gene mutations.

Authors:  Prathap Bandipalliam
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

7.  Predictive genetic testing in children: constitutional mismatch repair deficiency cancer predisposing syndrome.

Authors:  Zandrè Bruwer; Ursula Algar; Alvera Vorster; Karen Fieggen; Alan Davidson; Paul Goldberg; Helen Wainwright; Rajkumar Ramesar
Journal:  J Genet Couns       Date:  2013-10-15       Impact factor: 2.537

8.  Novel PMS2 pseudogenes can conceal recessive mutations causing a distinctive childhood cancer syndrome.

Authors:  Michel De Vos; Bruce E Hayward; Susan Picton; Eamonn Sheridan; David T Bonthron
Journal:  Am J Hum Genet       Date:  2004-04-07       Impact factor: 11.025

9.  Microsatellite instability in the peripheral blood leukocytes of HNPCC patients.

Authors:  Mary I Coolbaugh-Murphy; Jing-Ping Xu; Louis S Ramagli; Brian C Ramagli; Barry W Brown; Patrick M Lynch; Stanley R Hamilton; Marsha L Frazier; Michael J Siciliano
Journal:  Hum Mutat       Date:  2010-03       Impact factor: 4.878

10.  Thyroid cancer in a patient with a germline MSH2 mutation. Case report and review of the Lynch syndrome expanding tumour spectrum.

Authors:  Rein P Stulp; Johanna C Herkert; Arend Karrenbeld; Bart Mol; Yvonne J Vos; Rolf H Sijmons
Journal:  Hered Cancer Clin Pract       Date:  2008-02-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.